Seeking Alpha

Encouraging preliminary results for MEI's cancer drug

Preliminary results from a Phase 2a clinical trial of MEI Pharmaceuticals' (MEIP +16.4%) histone deacetylase (HDAC) inhibitor Pracinostat in combination with Vidaza (azacitidine) as a treatment for acute myeloid leukemia in elderly patients unsuitable for intensive chemotherapy suggest some patients would benefit greatly from the regimen. Of the first nine participants, two achieved a complete response and one achieved a complete response with incomplete blood count recovery after one or two treatment cycles. Three additional patients achieved either a partial response or partial response with incomplete blood count recovery.

The results met the pre-specified response rate allowing investigators to proceed to the Phase 2b stage.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs